Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 89532M101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
FMR LLC
13G/A
Amendment 2
|
8.8% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 8.8% | ||
| Abigail P. Johnson | 8.8% | ||
|
New Enterprise Associates 16, L.P.
13D/A
Amendment 9
|
10.5% |
5/7/2026
Event 5/5/2026
|
|
| New Enterprise Associates 16, L.P. | 10.5% | ||
| NEA Partners 16, L.P. | 10.5% | ||
| Nea 16 GP, LLC | 10.5% | ||
| NEA 18 Venture Growth Equity, L.P. | 10.5% | ||
| NEA Partners 18 VGE, L.P. | 10.5% | ||
| Nea 18 Vge GP, LLC | 10.5% | ||
| Forest Baskett | 9.8% | ||
| Ali Behbahani | 10.5% | ||
| Carmen Chang | 10.5% | ||
| Anthony A. Florence, Jr. | 10.5% | ||
| Mohamad H. Makhzoumi | 10.5% | ||
| Scott D. Sandell | 10.5% | ||
| Paul Walker | 10.5% | ||
|
FMR LLC
13G/A
Amendment 1
|
6.3% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 6.3% | ||
| Abigail P. Johnson | 6.3% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Rubric Capital Management LP
13G/A
Amendment 1
|
2.9% |
2/13/2026
Event 12/31/2025
|
|
| Rubric Capital Management LP | 2.9% | ||
| David Rosen | 2.9% | ||
|
New Enterprise Associates 16, L.P.
13D/A
Amendment 8
|
11.6% |
2/13/2026
Event 8/7/2025
|
|
| New Enterprise Associates 16, L.P. | 11.6% | ||
| NEA Partners 16, L.P. | 11.6% | ||
| Nea 16 GP, LLC | 11.6% | ||
| NEA 18 Venture Growth Equity, L.P. | 11.6% | ||
| NEA Partners 18 VGE, L.P. | 11.6% | ||
| Nea 18 Vge GP, LLC | 11.6% | ||
| Forest Baskett | 10.9% | ||
| Ali Behbahani | 11.6% | ||
| Carmen Chang | 11.6% | ||
| Anthony A. Florence, Jr. | 11.6% | ||
| Mohamad H. Makhzoumi | 11.6% | ||
| Scott D. Sandell | 11.6% | ||
| Paul Walker | 11.6% | ||
|
FMR LLC
13G
|
5.1% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 5.1% | ||
| Abigail P. Johnson | 5.1% | ||
| Vanguard Group Inc 13G | 5.0% |
1/30/2026
Event 12/31/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 5
|
7.0% |
11/14/2025
Event 9/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 7.0% | ||
| FHMLSP, L.P. | 7.0% | ||
| FHMLSP, L.L.C. | 7.0% | ||
| Frazier Life Sciences X, L.P. | 0.3% | ||
| FHMLS X, L.P. | 0.3% | ||
| FHMLS X, L.L.C. | 0.3% | ||
| Frazier Life Sciences XI, L.P. | 1.1% | ||
| FHMLS XI, L.P. | 1.1% | ||
| FHMLS XI, L.L.C. | 1.1% | ||
| James N. Topper | 0.3% | ||
| Patrick J. Heron | 0.3% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Viking Global Investors LP
13G/A
Amendment 5
|
4.2% |
11/14/2025
Event 9/30/2025
|
|
| Viking Global Investors LP | 4.2% | ||
| Viking Global Opportunities Parent GP LLC | 4.2% | ||
| Viking Global Opportunities GP LLC | 2.8% | ||
| Viking Global Opportunities Portfolio GP LLC | 2.8% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.8% | ||
| Viking Global Opportunities Drawdown GP LLC | 1.4% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.4% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.4% | ||
| Halvorsen Ole Andreas | 4.2% | ||
| Ott David C. | 4.2% | ||
| Shabet Rose Sharon | 4.2% | ||
| BlackRock, Inc. 13G | 5.6% |
10/17/2025
Event 9/30/2025
|
|
|
Viking Global Investors LP
13G/A
Amendment 4
|
5.9% |
8/14/2025
Event 6/30/2025
|
|
| Viking Global Investors LP | 5.9% | ||
| Viking Global Opportunities Parent GP LLC | 5.9% | ||
| Viking Global Opportunities GP LLC | 3.9% | ||
| Viking Global Opportunities Portfolio GP LLC | 3.9% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 3.9% | ||
| Viking Global Opportunities Drawdown GP LLC | 1.9% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.9% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.9% | ||
| Halvorsen Ole Andreas | 5.9% | ||
| Ott David C. | 5.9% | ||
| Shabet Rose Sharon | 5.9% | ||
|
New Enterprise Associates 16, L.P.
13D/A
Amendment 7
|
12.0% |
8/11/2025
Event 8/7/2025
|
|
| New Enterprise Associates 16, L.P. | 12.0% | ||
| NEA Partners 16, L.P. | 12.0% | ||
| Nea 16 GP, LLC | 12.0% | ||
| NEA 18 Venture Growth Equity, L.P. | 12.0% | ||
| NEA Partners 18 VGE, L.P. | 12.0% | ||
| Nea 18 Vge GP, LLC | 12.0% | ||
| Forest Baskett | 11.3% | ||
| Ali Behbahani | 12.0% | ||
| Carmen Chang | 12.0% | ||
| Anthony A. Florence, Jr. | 12.0% | ||
| Mohamad H. Makhzoumi | 12.0% | ||
| Scott D. Sandell | 12.0% | ||
| Paul Walker | 12.0% | ||
|
Rubric Capital Management LP
13G
|
7.1% |
7/9/2025
Event 6/30/2025
|
|
| Rubric Capital Management LP | 7.1% | ||
| David Rosen | 7.1% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 4
|
10.6% |
5/15/2025
Event 3/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 8.8% | ||
| FHMLSP, L.P. | 8.8% | ||
| FHMLSP, L.L.C. | 8.8% | ||
| Frazier Life Sciences X, L.P. | 0.4% | ||
| FHMLS X, L.P. | 0.4% | ||
| FHMLS X, L.L.C. | 0.4% | ||
| Frazier Life Sciences XI, L.P. | 1.4% | ||
| FHMLS XI, L.P. | 1.4% | ||
| FHMLS XI, L.L.C. | 1.4% | ||
| James N. Topper | 10.6% | ||
| Patrick J. Heron | 10.6% | ||
| Albert Cha | 8.8% | ||
| James Brush | 8.8% | ||
| Daniel Estes | 1.4% | ||
|
Viking Global Investors LP
13G/A
Amendment 3
|
8.7% |
5/15/2025
Event 3/31/2025
|
|
| Viking Global Investors LP | 8.7% | ||
| Viking Global Opportunities Parent GP LLC | 8.7% | ||
| Viking Global Opportunities GP LLC | 5.8% | ||
| Viking Global Opportunities Portfolio GP LLC | 5.8% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.8% | ||
| Viking Global Opportunities Drawdown GP LLC | 2.9% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.9% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.9% | ||
| Halvorsen Ole Andreas | 8.7% | ||
| Ott David C. | 8.7% | ||
| Shabet Rose Sharon | 8.7% | ||
|
New Enterprise Associates 16, L.P.
13D/A
Amendment 6
|
15.0% |
3/20/2025
Event 3/18/2025
|
|
| New Enterprise Associates 16, L.P. | 15.0% | ||
| NEA Partners 16, L.P. | 15.0% | ||
| Nea 16 GP, LLC | 15.0% | ||
| NEA 18 Venture Growth Equity, L.P. | 15.0% | ||
| NEA Partners 18 VGE, L.P. | 15.0% | ||
| Nea 18 Vge GP, LLC | 15.0% | ||
| Forest Baskett | 14.1% | ||
| Ali Behbahani | 15.0% | ||
| Carmen Chang | 15.0% | ||
| Anthony A. Florence, Jr. | 15.0% | ||
| Mohamad H. Makhzoumi | 15.0% | ||
| Scott D. Sandell | 15.0% | ||
| Paul Walker | 15.0% | ||
|
Venrock Healthcare Capital Partners II, L.P.
13G/A
Amendment 4
|
1.4% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners II, L.P. | 1.4% | ||
| VHCP Co-Investment Holdings II, LLC | 1.4% | ||
| VHCP Management II, LLC | 1.4% | ||
| Venrock Healthcare Capital Partners III, L.P. | 1.4% | ||
| VHCP Co-Investment Holdings III, LLC | 1.4% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 1.4% | ||
| VHCP Management III, LLC | 1.4% | ||
| VHCP Management EG, LLC | 1.4% | ||
| Nimish Shah | 1.4% | ||
| Bong Y Koh | 1.4% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 3
|
11.9% |
2/14/2025
Event 12/31/2024
|
|
| Frazier Life Sciences Public Fund, L.P. | 9.9% | ||
| FHMLSP, L.P. | 9.9% | ||
| FHMLSP, L.L.C. | 9.9% | ||
| Frazier Life Sciences X, L.P. | 0.5% | ||
| FHMLS X, L.P. | 0.5% | ||
| FHMLS X, L.L.C. | 0.5% | ||
| Frazier Life Sciences XI, L.P. | 1.6% | ||
| FHMLS XI, L.P. | 1.6% | ||
| FHMLS XI, L.L.C. | 1.6% | ||
| James N. Topper | 11.9% | ||
| Patrick J. Heron | 11.9% | ||
| Albert Cha | 9.9% | ||
| James Brush | 9.9% | ||
| Daniel Estes | 1.6% | ||
|
Rosalind Advisors, Inc.
13G/A
Amendment 4
|
1.2% |
2/13/2025
Event 2/13/2025
|
|
| Rosalind Advisors, Inc. | 1.2% | ||
| Salamon Steven A J | 1.2% | ||
| Aharon Gil | 1.2% | ||
| Rosalind Master Fund L.P. | 1.2% | ||
|
Rubric Capital Management LP
13G/A
Amendment 3
|
4.7% |
2/13/2025
Event 12/31/2024
|
|
| Rubric Capital Management LP | 4.7% | ||
| David Rosen | 4.7% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 30.1 k | $430 k |
| 2026 Q2 | 227 | 153 M | $2.90 B |
| 2026 Q1 | 209 | 135 M | $1.61 B |
| 2025 Q4 | 196 | 130 M | $1.63 B |
| 2025 Q3 | 175 | 129 M | $1.18 B |
| 2025 Q2 | 166 | 115 M | $632 M |
| 2025 Q1 | 145 | 88.2 M | $554 M |
| 2024 Q4 | 118 | 81.5 M | $338 M |
| 2024 Q3 | 100 | 58.2 M | $194 M |
| 2024 Q2 | 82 | 58.8 M | $175 M |
| 2024 Q1 | 86 | 51.7 M | $178 M |
| 2023 Q4 | 69 | 52.5 M | $70.4 M |
| 2023 Q3 | 57 | 48.7 M | $106 M |
| 2023 Q2 | 56 | 48.8 M | $117 M |
| 2023 Q1 | 39 | 43.5 M | $80.4 M |
| 2022 Q4 | 41 | 43.3 M | $83.5 M |
| 2022 Q3 | 41 | 45.8 M | $70.5 M |
| 2022 Q2 | 33 | 28.8 M | $80.8 M |
| 2022 Q1 | 24 | 7.16 M | $32.9 M |
| 2021 Q4 | 18 | 13.2 M | $10.3 M |
| 2021 Q3 | 19 | 12.4 M | $17.4 M |
| 2021 Q2 | 18 | 12.5 M | $28.1 M |
| 2021 Q1 | 20 | 13.1 M | $35.6 M |
| 2020 Q4 | 20 | 13.0 M | $31.8 M |
| 2020 Q3 | 17 | 13.3 M | $53.5 M |
| 2020 Q2 | 17 | 13.4 M | $88.0 M |
| 2020 Q1 | 22 | 14.0 M | $45.9 M |
| 2019 Q4 | 18 | 14.2 M | $53.3 M |
| 2019 Q3 | 22 | 20.4 M | $92.0 M |
| 2019 Q2 | 19 | 14.2 M | $106 M |